Literature DB >> 26029896

Examining the potential role of a supervised injection facility in Saskatoon, Saskatchewan, to avert HIV among people who inject drugs.

Ehsan Jozaghi1, Asheka Jackson1.   

Abstract

BACKGROUND: Research predicting the public health and fiscal impact of Supervised Injection Facilities (SIFs), across different cities in Canada, has reported positive results on the reduction of HIV cases among People Who Inject Drugs (PWID). Most of the existing studies have focused on the outcomes of Insite, located in the Vancouver Downtown Eastside (DTES). Previous attention has not been afforded to other affected areas of Canada. The current study seeks to address this deficiency by assessing the cost-effectiveness of opening a SIF in Saskatoon, Saskatchewan.
METHODS: We used two different mathematical models commonly used in the literature, including sensitivity analyses, to estimate the number of HIV infections averted due to the establishment of a SIF in the city of Saskatoon, Saskatchewan.
RESULTS: Based on cumulative cost-effectiveness results, SIF establishment is cost-effective. The benefit to cost ratio was conservatively estimated to be 1.35 for the first two potential facilities. The study relied on 34% and 14% needle sharing rates for sensitivity analyses. The result for both sensitivity analyses and the base line estimates indicated positive prospects for the establishment of a SIF in Saskatoon.
CONCLUSION: The opening of a SIF in Saskatoon, Saskatchewan is financially prudent in the reduction of tax payers' expenses and averting HIV infection rates among PWID.
© 2015 by Kerman University of Medical Sciences.

Entities:  

Keywords:  Canada; Cost-Benefit Analysis; HIV; People Who Inject Drugs (PWID)

Mesh:

Year:  2015        PMID: 26029896      PMCID: PMC4450732          DOI: 10.15171/ijhpm.2015.73

Source DB:  PubMed          Journal:  Int J Health Policy Manag        ISSN: 2322-5939


  34 in total

1.  Needle exchange is not enough: lessons from the Vancouver injecting drug use study.

Authors:  S A Strathdee; D M Patrick; S L Currie; P G Cornelisse; M L Rekart; J S Montaner; M T Schechter; M V O'Shaughnessy
Journal:  AIDS       Date:  1997-07       Impact factor: 4.177

2.  Changes in public order after the opening of a medically supervised safer injecting facility for illicit injection drug users.

Authors:  Evan Wood; Thomas Kerr; Will Small; Kathy Li; David C Marsh; Julio S G Montaner; Mark W Tyndall
Journal:  CMAJ       Date:  2004-09-28       Impact factor: 8.262

3.  Safer injection facility use and syringe sharing in injection drug users.

Authors:  Thomas Kerr; Mark Tyndall; Kathy Li; Julio Montaner; Evan Wood
Journal:  Lancet       Date:  2005 Jul 23-29       Impact factor: 79.321

4.  Needle exchange programs: an economic evaluation of a local experience.

Authors:  M Gold; A Gafni; P Nelligan; P Millson
Journal:  CMAJ       Date:  1997-08-01       Impact factor: 8.262

5.  An opportunity lost: HIV infections associated with lack of a national needle-exchange programme in the USA.

Authors:  P Lurie; E Drucker
Journal:  Lancet       Date:  1997-03-01       Impact factor: 79.321

6.  Cost effectiveness of Streetworks' needle exchange program of Edmonton.

Authors:  P Jacobs; P Calder; M Taylor; S Houston; L D Saunders; T Albert
Journal:  Can J Public Health       Date:  1999 May-Jun

7.  Potential use of safer injecting facilities among injection drug users in Vancouver's Downtown Eastside.

Authors:  Thomas Kerr; Evan Wood; Dan Small; Anita Palepu; Mark W Tyndall
Journal:  CMAJ       Date:  2003-10-14       Impact factor: 8.262

8.  Use of supervised injection facilities and injection risk behaviours among young drug injectors.

Authors:  María J Bravo; Luis Royuela; Luis De la Fuente; María T Brugal; Gregorio Barrio; Antonia Domingo-Salvany
Journal:  Addiction       Date:  2009-02-10       Impact factor: 6.526

9.  The cost-effectiveness of Vancouver's supervised injection facility.

Authors:  Ahmed M Bayoumi; Gregory S Zaric
Journal:  CMAJ       Date:  2008-11-18       Impact factor: 8.262

10.  Cost and cost-effectiveness of increasing access to sterile syringes and needles as an HIV prevention intervention in the United States.

Authors:  D R Holtgrave; S D Pinkerton; T S Jones; P Lurie; D Vlahov
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998
View more
  5 in total

1.  Longitudinal Factors Associated with Used Syringe Lending Among HIV-Positive Antiretroviral Therapy-Naïve People Who Inject Drugs in a Canadian Setting.

Authors:  Ezequiel Blumenkrans; M Eugenia Socías; Lindsey Richardson; Thomas Kerr; Jean Shoveller; Julio Montaner; M-J Milloy
Journal:  AIDS Behav       Date:  2020-07

2.  Health programmes and services addressing the prevention and management of infectious diseases in people who inject drugs in Canada: a systematic integrative review.

Authors:  Katrina Bouzanis; Siddharth Joshi; Cynthia Lokker; Sureka Pavalagantharajah; Yun Qiu; Hargun Sidhu; Lawrence Mbuagbaw; Majdi Qutob; Alia Henedi; Mitchell A H Levine; Robin Lennox; Jean-Eric Tarride; Dale Kalina; Elizabeth Alvarez
Journal:  BMJ Open       Date:  2021-09-23       Impact factor: 3.006

3.  Mitigating the heroin crisis in Baltimore, MD, USA: a cost-benefit analysis of a hypothetical supervised injection facility.

Authors:  Amos Irwin; Ehsan Jozaghi; Brian W Weir; Sean T Allen; Andrew Lindsay; Susan G Sherman
Journal:  Harm Reduct J       Date:  2017-05-12

4.  Qualitative assessment of patients' perspectives and needs from community pharmacists in substance use disorder management.

Authors:  Sarah Fatani; Daniel Bakke; Marcel D'Eon; Anas El-Aneed
Journal:  Subst Abuse Treat Prev Policy       Date:  2021-05-01

5.  Feasibility, acceptability, concerns, and challenges of implementing supervised injection services at a specialty HIV hospital in Toronto, Canada: perspectives of people living with HIV.

Authors:  Katherine Rudzinski; Jessica Xavier; Adrian Guta; Soo Chan Carusone; Kenneth King; J Craig Phillips; Sarah Switzer; Bill O'Leary; Rosalind Baltzer Turje; Scott Harrison; Karen de Prinse; Joanne Simons; Carol Strike
Journal:  BMC Public Health       Date:  2021-07-29       Impact factor: 3.295

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.